UCSF

Topics and Expertise: QBI Coronavirus Research Group

UCSF Quantitative Biosciences Institute and Institut Pasteur form center to fight infectious disease

QBI Director Krogan receives the Legion of Honor, France’s highest award

Beyond the spike protein

Findings from QBI point to a host of viral proteins that enable SARS-CoV-2 variants to evade the immune system.

Cancer drug stops SARS-CoV-2 in the lab

“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.

QBI probes three lethal coronaviruses to find possible drug targets

“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.

Danica Fujimori Receives Bowes Biomedical Investigator Award

Danica Galonić Fujimori, PhD, will receive $1.25 million in funding over the next five years from the endowment of the late William K. Bowes, Jr., a venture capitalist and longtime UCSF supporter.

Nanobody-based antiviral developed at UCSF effectively blocks SARS-CoV-2 in the lab

School scientists developed an antiviral that fights SARS-CoV-2 that can be given as a nasal spray.

How targeting a key SARS-CoV-2 enzyme could lead to an antiviral drug

The chemical fragments could bind to and disable an enzyme that helps the virus replicate.

SARS-CoV-2 may spur growth of molecular “railways” out of infected cells, School scientists show

UCSF-led collaboration uncovers new avenues for COVID-19 drug discovery

QBI Coronavirus Research Group identifies drugs that block SARS-CoV-2 in the laboratory

The QBI Coronavirus Research Group found six drugs that effectively beat back SARS-COV-2 in the laboratory.

Pages